General features of 406 patients with psoriatic arthritis
| Overall (n=406) | Uveitis (n=20) | Non-uveitis (n=386) | P value* | |
| Main general features | ||||
| Age (years), mean±SD | 46.3±12.3 | 43.1±14.5 | 46.5±12.2 | 0.23 |
| Sex (women/men), n (% of women) | 202/204 (49.8) | 12/8 (60/40) | 218/168 (56.5/43.5) | 0.76 |
| HLA-B27 positive, n (%) | 38 (9.4) | 9 (45) | 29 (7.5) | 0.0001 |
| PsA duration, years, mean±SD | 9.9±8.2 | 12.7±9.2 | 9.8±8.2 | 0.13 |
| Delayed PsA diagnosis, years, median (IQR) | 1.0 (0.0–3.0) | 1.0 (0.0–2.0) | 1.0 (0.0–3.0) | 0.23 |
| PsA characteristics, n (%) | ||||
| Axial pattern | 48 (11.8) | 4 (20) | 44 (11.4) | 0.28 |
| Peripheral pattern | 236 (58.1) | 12 (60) | 224 (58) | 0.86 |
| Mixed pattern | 122 (30.1) | 4 (20) | 118 (30.6) | 0.32 |
| Enthesitis | 152 (37.4) | 8 (40) | 144 (37.3) | 0.81 |
| Dactylitis | 98 (24.1) | 5 (25) | 93 (24.1) | 0.99 |
| PsA scores | ||||
| BASDAI, mean±SD | 2.7±2.6 | 3.1±1.3 | 2.6±2.6 | 0.49 |
| BASFI, median (IQR) | 1.2 (0.0–4.0) | 4.0 (1.6–5.0) | 1.0 (0.0–3.5) | 0.01 |
| PsAID, median (IQR) | 1.4 (0.0–3.5) | 5.9 (2.1–6.8) | 1.25 (0.0–3.0) | 0.001 |
| DAPSA >4, n (%) | 65 (16) | 6 (30) | 59 (15.3) | 0.11 |
| PASI, mean±SD | 1.5±0.7 | 3.9±3.4 | 1.9±0.4 | 0.25 |
| Radiological features, n (%) | ||||
| Sacroiliitis on MRI† | 37 (9.1) | 5 (25) | 32 (8.3) | 0.027 |
| Other extraarticular manifestations, n /% | ||||
| Inflammatory bowel disease | 21 (5.2) | 2 (10) | 19 (4.9) | 0.28 |
| Ocular surface pathology | 5 (1.2) | 2 (10) | 3 (0.8) | 0.021 |
| Comorbidity, n (%) | ||||
| Hypertension | 149 (36.7) | 7 (35) | 142 (36.8) | 0.87 |
| Diabetes | 47 (11.6) | 3 (15) | 44 (11.4) | 0.72 |
| Dyslipaemia | 201 (49.5) | 8 (40) | 193 (50) | 0.383 |
| Patients treated with systemic non-bDMARDs, n (%) | ||||
| Corticosteroids | 179 (44.1) | 8 (40) | 171 (43.3) | 0.38 |
| NSAIDs | 348 (85.7) | 18 (90) | 330 (85.5) | 0.75 |
| cDMARDs | 328 (80.8) | 15 (75) | 313 (81.1) | 0.56 |
| Patients on bDMARDs, n (%) | 137 (33.7) | 8 (40) | 129 (33.4) | 0.42 |
| bDMARDs received, n (%) | ||||
| Etanercept | 21 (5.2) | 1 (5) | 20 (5.2) | 0.99 |
| TNFi monoclonal antibodies | 101 (24.9) | 7 (35) | 94 (24.4) | 0.29 |
| Secukinumab | 18 (4.4) | 1 (5) | 17 (4.4) | 0.61 |
Area and Severity Index score.
Comparison between patients with and without uveitis.
*P value: for comparison between patients with PsA who developed uveitis and who did not.
†Sacroiliitis on MRI was evaluated in patients with low back inflammatory pain.
.BASDAI, Bath Ankylosing Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; bDMARDs, biological disease modifying antirheumatic drug; cDMARDs, conventional DMARDs; DAPSA, Disease Activity Index for Psoriatic Arthritis; NSAIDs, Nonsteroidal anti-inflammatory drugs; PASI, psoriasis; PsA, psoriatic arthritis; PsAID, PsA impact of Disease Score.